Yes, I got that. My point is the p1 for K is broad spectrum against at least 6 regional solid tumor cancers and more than a dozen tumor types. The study you cite, all 20 patients had the specific type AML. K would show inadequate sample for each type, while Ageos showed 3 CR of 6 reportable cases. Again, K doesn't even have 3 patients for any particular type. I don't know how to make my thoughts on this any more clear. Maybe TOB can elaborate on statistical significance and sufficient sample.
News 
Market Data 
Discover 
